Relay Therapeutics Shares Jump After Interim Data From Bile Duct Cancer Drug Ahead Of ESMO Presentation

Relay Therapeutics Inc's RLAY ReFocus trial for RLY-4008 was published on the European Society for Medical Oncology's (ESMO) website.
The abstract has been selected for an oral presentation at the upcoming ESMO Congress 2022.
Relay Therapeutics is evaluating RLY-4008, its bile duct cancer drug, for a narrow group of patients with FGFR2-altered cholangiocarcinoma.
Related: Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial.
Potent efficacy was observed across all doses, particularly at the recommended phase 2 dose (RP2D) of 70mg QD with an objective response rate of 88%.
One patient treated at the RP2D had a near-complete response and subsequent tumor resection with curative intent.
DOR is not yet mature, with the majority of responses ongoing.
Across all doses (N=195), the most common treatment-related AEs (TRAEs) were low-grade stomatitis (48%), PPE (46%), and dry mouth (31%). No grade 4/5 TRAEs were observed.
Price Action: RLAY shares are up 19.50% at $30.30 on the last check Thursday.